JP2016540811A5 - - Google Patents

Download PDF

Info

Publication number
JP2016540811A5
JP2016540811A5 JP2016540686A JP2016540686A JP2016540811A5 JP 2016540811 A5 JP2016540811 A5 JP 2016540811A5 JP 2016540686 A JP2016540686 A JP 2016540686A JP 2016540686 A JP2016540686 A JP 2016540686A JP 2016540811 A5 JP2016540811 A5 JP 2016540811A5
Authority
JP
Japan
Prior art keywords
compound
phenyl
optionally substituted
oxy
acetyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016540686A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016540811A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2014/066707 external-priority patent/WO2015092610A1/en
Publication of JP2016540811A publication Critical patent/JP2016540811A/ja
Publication of JP2016540811A5 publication Critical patent/JP2016540811A5/ja
Withdrawn legal-status Critical Current

Links

JP2016540686A 2013-12-20 2014-12-08 N−アシルピペリジンエーテルトロポミオシン関連キナーゼ阻害剤 Withdrawn JP2016540811A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361918783P 2013-12-20 2013-12-20
US61/918,783 2013-12-20
PCT/IB2014/066707 WO2015092610A1 (en) 2013-12-20 2014-12-08 N-acylpiperidine ether tropomyosin-related kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2016540811A JP2016540811A (ja) 2016-12-28
JP2016540811A5 true JP2016540811A5 (https=) 2017-12-28

Family

ID=52440728

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016540686A Withdrawn JP2016540811A (ja) 2013-12-20 2014-12-08 N−アシルピペリジンエーテルトロポミオシン関連キナーゼ阻害剤

Country Status (5)

Country Link
US (1) US20170305857A1 (https=)
EP (1) EP3083602A1 (https=)
JP (1) JP2016540811A (https=)
CA (1) CA2934010A1 (https=)
WO (1) WO2015092610A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016009296A1 (en) * 2014-07-16 2016-01-21 Pfizer Inc. N-acylpiperidine ether tropomyosin-related kinase inhibitors
WO2016020784A1 (en) * 2014-08-05 2016-02-11 Pfizer Inc. N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
EP3532464A4 (en) 2016-10-28 2020-07-08 Icahn School of Medicine at Mount Sinai COMPOSITIONS AND METHODS FOR THE TREATMENT OF EZH2 MEDIATION CANCER
JP7234201B2 (ja) * 2017-07-12 2023-03-07 ブリストル-マイヤーズ スクイブ カンパニー 心不全の治療のためのrockの5員アミノヘテロ環および5,6-または6,6員二環式アミノヘテロ環の阻害剤
CA3104298A1 (en) 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Wd40 repeat domain protein 5 (wdr5) degradation / disruption compounds and methods of use
EP3817745A4 (en) * 2018-07-05 2022-04-06 Icahn School of Medicine at Mount Sinai PROTEIN TYROSINE KINASE 6 (PTK6) DEGRADATION/DISPUTED COMPOUNDS AND METHODS OF USE
CN109970631A (zh) * 2019-03-26 2019-07-05 上海吉奉生物科技有限公司 一种5-碘-2-吡啶乙酸的合成方法
CN118908962A (zh) 2019-05-06 2024-11-08 西奈山伊坎医学院 作为hpk1的降解剂的异双功能化合物
US12103924B2 (en) 2020-06-01 2024-10-01 Icahn School Of Medicine At Mount Sinai Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
CN116396298A (zh) * 2023-06-06 2023-07-07 四川维亚本苑生物科技有限公司 CDK Ligand-1的中间体XII及CDK Ligand-1的制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3958002A (en) 1972-06-20 1976-05-18 Pierre Fabre S.A. Medicaments having psychotropic properties (antitussives)
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
UA80171C2 (en) 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
BRPI0410654A (pt) * 2003-06-12 2006-06-20 Novo Nordisk As composto, composição farmacêutica, uso de um composto, método para tratar um distúrbio de um paciente, e, processo para a preparação de um composto
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
MXPA06013805A (es) 2004-05-27 2007-02-02 Pfizer Prod Inc Derivados de pirrolopirimidina de utilidad en el tratamiento contra el cancer.
WO2006028029A1 (ja) 2004-09-07 2006-03-16 Sankyo Company, Limited 置換ビフェニル誘導体
US8071768B2 (en) * 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
US7405302B2 (en) 2005-10-11 2008-07-29 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (FLAP) inhibitors
GB0526107D0 (en) 2005-12-22 2006-02-01 Angeletti P Ist Richerche Bio Therapeutic Compounds
RU2323058C1 (ru) 2006-07-12 2008-04-27 ООО Научно-внедренческий центр "Машины и оборудование для энергетики" Способ формирования наружной резьбы на концевом участке трубной заготовки
US20110172230A1 (en) * 2006-08-23 2011-07-14 Takahiro Ishii Urea compound or salt thereof
AU2007336811A1 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
JP5361857B2 (ja) 2007-03-23 2013-12-04 ファイザー・リミテッド イオンチャネルの阻害剤
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン,インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
WO2009143018A2 (en) 2008-05-19 2009-11-26 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
PE20091846A1 (es) 2008-05-19 2009-12-16 Plexxikon Inc DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS
US8110576B2 (en) 2008-06-10 2012-02-07 Plexxikon Inc. Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications
US8119637B2 (en) 2008-06-10 2012-02-21 Plexxikon Inc. Substituted pyrrolo[2,3-b]pyrazines and methods for kinase modulation, and indications therefor
HUE025013T2 (hu) 2009-01-12 2016-04-28 Pfizer Ltd Szulfonamid-származékok
CN102438991B (zh) 2009-04-29 2015-08-26 兴和株式会社 具有杂环连接基的甲醇化合物
WO2011021645A1 (ja) * 2009-08-19 2011-02-24 大日本住友製薬株式会社 2環性ウレア誘導体、またはその薬学的に許容される塩
TWI619713B (zh) 2010-04-21 2018-04-01 普雷辛肯公司 用於激酶調節的化合物和方法及其適應症
ES2581848T3 (es) 2011-04-05 2016-09-07 Pfizer Limited Derivados de pirrolo[2,3-d]pirimidina como inhibidores de quinasas relacionadas con tropomiosina
AU2012256237B2 (en) 2011-05-13 2017-01-05 Array Biopharma Inc. Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as TrkA kinase inhibitors
CA2841757A1 (en) 2011-07-15 2013-01-24 Etzer Darout Gpr 119 modulators
KR20140105508A (ko) 2011-12-12 2014-09-01 닥터 레디스 레보러터리즈 리미티드 트로포미오신 수용체 키나제(Trk) 억제제인 치환된 피라졸로[1,5-a]피리딘
TW201350479A (zh) 2012-04-26 2013-12-16 Ono Pharmaceutical Co Trk阻害化合物

Similar Documents

Publication Publication Date Title
JP2016540811A5 (https=)
JP2018519323A5 (https=)
JP2016535772A5 (https=)
JP2017530999A5 (https=)
JP2016516043A5 (https=)
JP2014526549A5 (https=)
RU2013143028A (ru) Тиазолилфенилбензолсульфонамидопроизводные в качестве ингибиторов киназ
RU2017127135A (ru) Терапевтическое средство против рака желчных протоков
JP2013545791A5 (https=)
JP2014511869A5 (https=)
JP2015524472A5 (https=)
JP2014528464A5 (https=)
JP2016540742A5 (https=)
JP2016503009A5 (https=)
JP2016513660A5 (https=)
RU2012116877A (ru) Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы
RU2017116598A (ru) Соединения и композиции для модуляции киназной активности мутантов egfr
JP2009534386A5 (https=)
HRP20170112T1 (hr) Supstituirani spojevi piridin-2-karboksamida kao kinazni inhibitori signalne regulacije apoptoze
JP2017537882A5 (https=)
JP2013539791A5 (https=)
RU2017116196A (ru) 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1
JP2017530185A5 (https=)
RU2015104962A (ru) Ди- и тригетероарильные производные в качестве ингибиторов агрегации белков
JP2014516070A5 (https=)